ArticleBlood advances2018
Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous
Article in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review.Blood cancer journal · 2024Pooled it
- Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.British journal of haematology · 2021Trial
- Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients.Blood cancer journal · 2020Trial
- Rapid Recognition of Carfilzomib-Induced Thrombotic Microangiopathy and Early Application of Eculizumab Successfully Rescued Two Relapsed Myeloma Patients.Chronic diseases and translational medicine · 2026Article
- Management of Atypical Haemolytic Uraemic Syndrome With Triggers: Diagnostic and Treatment Algorithms From an Asia-Pacific Perspective.Nephrology (Carlton, Vic.) · 2025Review
- Proteasome inhibitor-associated thrombotic microangiopathy: a real-world retrospective and pharmacovigilance database analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Delayed Onset of Thrombotic Microangiopathy (TMA) upon Prolonged Carfilzomib Therapy in Multiple Myeloma: A Case Report and Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Review
- Carfilzomib-induced thrombotic microangiopathy (TMA) refractory to eculizumab: A case report and literature review.Annals of hematology · 2024Review
- Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA.Blood cancer journal · 2023Article
- Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition.BMC nephrology · 2023Article
- Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy.Blood cancer journal · 2023Article
- Carfilzomib Induced Microangiopathy due to Accumulation With Paxlovid.Kidney international reports · 2022Article
- Simultaneous Cases of Carfilzomib-Induced Thrombotic Microangiopathy in 2 Patients With Multiple Myeloma.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2022Article
- The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies.Journal of thrombosis and haemostasis : JTH · 2022Review
- Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls.Journal of clinical medicine · 2022Article
- Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis.Journal of medical cases · 2022Article
- Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and therapeutic success.BMJ case reports · 2021Article
- Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.BMC nephrology · 2021Article
- Hemolytic uremic syndrome and kidney transplantation in uncontrolled donation after circulatory death (DCD): A two-case report.Clinical nephrology. Case studies · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.